MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

Trial Parameters

Brief Summary

To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.

Eligibility Criteria

Inclusion Criteria: * Kidney transplant recipient at our Institution * Liver transplant recipient at our Institution Exclusion Criteria: * Re-transplantation * Dual kidney transplantation * Combined transplant (kidney-liver, kidney-pancreas) * Autoimmune disease as indication to transplant

Related Trials